Prof. Dr. Hans Lehrach is a distinguished molecular geneticist and systems biologist. 

After earning his Ph.D. from the Max Planck Institute in Göttingen, he conducted postdoctoral research at Harvard University. He subsequently led research groups at EMBL-Heidelberg and at the the Imperial Cancer Research Fund (London), where he advanced genome analysis technologies, including the development of array-based robotics for large-scale genome mapping and analysis. In 1994, he became Director at the Max Planck Institute for Molecular Genetics in Berlin, focusing on functional genomics, genome sequencing, and cancer systems medicine. ​

Prof. Lehrach played a pivotal role in the Human Genome Project. His research has significantly advanced omics technologies. Prof. Hans Lehrach has co-authored over 1,200 scientific publications. He has co-founded several biotechnology companies, including Sequana Therapeutics, GPC Biotech, Scienion, Prot@gen, PSF Biotech, Atlas Biolabs, and Alacris Theranostics.  Currently, Prof. Lehrach focuses on developing »digital twins«—computational models that simulate individual patients to optimize treatment strategies—advancing personalized medicine.